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Abstract
Although there are no effective disease-modifying therapies for mitochondrial diseases, an increasing number of trials are being
conducted in this rare disease group. The use of sensitive and valid endpoints is essential to test the effectiveness of potential
treatments. There is no consensus on which outcome measures to use in children with mitochondrial disease. The aims of this
two-day Delphi-based workshop were to (i) define the protocol for an international, multi-centre natural history study in children
with mitochondrial myopathy and (ii) to select appropriate outcome measures for a validation study in children with mitochon-
drial encephalopathy. We suggest two sets of outcome measures for a natural history study in children with mitochondrial
myopathy and for a proposed validation study in children with mitochondrial encephalopathy.
Introduction
Thirteen researchers from five different countries (seven dif-
ferent mitochondrial medicine centres in the UK, USA,
Czech Republic, Italy and the Netherlands) met in Vianen,
the Netherlands from 1 to 2 March 2018 to discuss which
outcome measures would be best to use in clinical trials for
children with mitochondrial myopathy and mitochondrial en-
cephalopathy. The aims of the workshop were to (i) define the
protocol for an international, multi-centre natural history study
in children with mitochondrial myopathy and (ii) to select
appropriate outcome measures for a validation study in chil-
dren with mitochondrial encephalopathy.
Background
Mitochondrial diseases are an important group of inherited
disorders (Rahman and Rahman 2018), with an estimated
prevalence of 1 in 5000 live births (Chinnery and Turnbull
2001; Schaefer et al. 2008; Gorman et al. 2016). The term
Bmitochondrial diseases^, although in strict sense much
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broader, is reserved here for disorders directly affecting the
function of the oxidative phosphorylation system.
Mitochondrial diseases can be caused by mutations in mito-
chondrial or nuclear DNA (Leonard and Schapira 2000a, b).
Paediatric mitochondrial diseases mostly present with a
multi-system phenotype mainly involving tissues with high
energy demands, such as the brain, retina, heart, kidney
and skeletal muscle (Koopman et al. 2016). For practical
reasons, we divided the extremely complex and heteroge-
neous clinical presentations of individual mitochondrial
disease into two phenotypes: mitochondrial encephalopa-
thy, where the central nervous system has the most prom-
inent signs and symptoms, and mitochondrial myopathy, in
which the clinical disease expression is dominated by mus-
cle involvement.
Mitochondrial myopathy is a heterogeneous entity with
variable severity, aetiology and prognosis. Symptoms in early
childhood include feeding problems with poor sucking and,
consequently, poor weight gain, hypotonia and delayed motor
development. At later age, (proximal) myopathy, exercise in-
tolerance, fatigue, ptosis and external ophthalmoplegia are the
most prevalent symptoms. Some patients may be severely
limited in their daily activities and fully dependent on wheel-
chairs and help from caretakers, while others manage to live a
reasonably normal life despite their reduced physical capacity
(Debray et al. 2007). Some patients with mitochondrial my-
opathy will develop multi-system disease symptoms later in
life, including cardiomyopathy, optic atrophy or sensorineural
deafness (de Laat et al. 2012).
The signs and symptoms of patients with mitochondrial
encephalopathy are, as with mitochondrial myopathies, highly
heterogeneous, ranging from early fatal epilepsy syndromes to
episodic migraine at later age. Children typically present with
psychomotor retardation and failure to thrive, with or without
other neurological features, such as hypotonia, spasticity and
epilepsy (Skladal et al. 2003). Depression, behavioural prob-
lems and psychosis may complicate the course of the disease
(Koene et al. 2009). Brain magnetic resonance imaging (MRI)
may show specific or non-specific abnormalities (Valanne et
al. 1998), although many have no visible abnormalities on
MRI. This highly heterogeneous group of patients mostly
shows a variable intellectual disability, which frequently re-
quires the patient to attend a special school and/or remain
dependent on caretakers (Debray et al. 2007). Also, in mito-
chondrial encephalopathy, multiple organ systems may be
involved.
While an increasing number of clinical trials is emerging
for mitochondrial disease, there is a paucity of effective ther-
apies (Gorman et al. 2016; Koopman et al. 2016; Viscomi
2016). To define the effectiveness of any new pharmacologic
agent, well-designed clinical studies need to be executed.
Previously, a Cochrane review on treatment studies in patients
with mitochondrial disease stated that the quality of many of
the previously performed studies is poor (Pfeffer et al. 2013).
One of the main problems arising in these low-quality studies
includes the heterogeneity of the often small-numbered study
population and the lack of sufficiently sensitive patient-
centred outcome measures.
To prepare for clinical trials in children with mitochondrial
diseases, the phenotype and natural disease course of children
with mitochondrial disease should be well known (Keshavan
2018). Only if the complaints, symptoms and functional abil-
ities and their variability or progression over time are clear can
appropriate outcome measures be selected.
Based on the knowledge of the clinical spectrum of the
disease, the disease course and the functional abilities of the
patients, outcome measures can be selected. Selection of an
outcome measure should take into account the final aim of
using it, namely to detect a clinically relevant difference be-
tween the active and the placebo group. The regulatory agen-
cies [e.g. the European Medicines Agency (EMA) and the
U.S. Food and Drug Administration (FDA)] prefer the di-
rect measurement of Bhow a patient feels, functions or
survives^, using functional outcome measures and
patient-reported outcome measures (FDA 2009). A recent
study evaluating the effectiveness of orphan medicinal
products in the real world deemed that the use of a clinical
or validated surrogate primary endpoint seemed to be re-
lated to effectiveness in the real world (Schuller et al.
2017). This stresses the importance of not only selecting
a clinically relevant endpoint but also the accurate valida-
tion of surrogate endpoints. Surrogate endpoints can only
substitute for a clinical endpoint when there is confirma-
tion of a strong relation with the pathophysiology of the
disease, clinical response to therapy and the prediction of
clinical benefit (Schuller et al. 2017). Although validated
surrogate endpoints are suitable for early-stage clinical tri-
als, clinical and functional endpoints are the closest reflec-
tion of patients’ functioning and should be used in later
stages of drug development (Cox 2018).
There have been several initiatives to harmonise clinical
and functional outcome measures for children with mitochon-
drial disease. In 2013, some of our group published a review
on which outcome measures can be used for children with
mitochondrial diseases, based on the experience in other dis-
eases (Koene et al. 2013). Nearly 4 years later, a group of
researchers gathered in Rome, Italy to identify outcome mea-
sures for children and adults with mitochondrial myopathy
(Mancuso et al. 2017). As a follow-up to the workshop in
Rome, this workshop aimed to establish consensus on which
outcome measures to use in natural history studies in children
with mitochondrial myopathy, based on experience with these
outcome measures in a validation study and in daily practice.
The aim of the second day was to identify outcome measures
to be investigated in a validation study in children with mito-
chondrial encephalopathy.
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Methods
Delphi-based method
The Delphi method provides a systematic approach to collect
opinions from experts (the BDelphi panel^) and has been used
to obtain consensus or to provide recommendations on a well-
defined and specified topic (Jorm 2015). In this method, ex-
perts provide their opinions anonymously, on an individual
and independent basis. In our case, we have used several ele-
ments of this method to guide our workshop (therefore, called
Delphi-based method). We brought a wide range of interna-
tional experts in mitochondrial medicine and neuromuscular
disease with diverse professional backgrounds together. The
experts were provided with background information and dis-
cussions before they expressed their opinions. Moreover, a
second voting round was executed after presentation and dis-
cussion of the results in the first voting round, allowing an
iterative process.
Pre-meeting
Experts from established centres of excellence in the diagnosis
and management of children with mitochondrial disease were
invited for a two-day workshop on outcome measures in pae-
diatric mitochondrial disease. The Delphi panel consisted of
three metabolic paediatricians, three paediatric neurologists,
one paediatric rehabilitation specialist, one clinical pharma-
cologist with a special interest in trial design in mitochondrial
disease and five paediatric physiotherapists with a broad clin-
ical background. Participants were asked to give their input for
functional outcome measures they thought were suitable to
measure disease progression in a natural history study, based
on their clinical experience. All participants were asked to
prepare a short introduction about two to four of the outcome
measures in the list and the measurement properties in patients
with mitochondrial disease and—when not available—in oth-
er diseases.
Meeting
Both days started with a presentation on mitochondrial myop-
athy and mitochondrial encephalopathy, respectively, where
the clinical spectrum of the disease was illustrated by one of
the experienced physicians. Subsequently, all participants pre-
sented one or more outcomemeasures, including the measure-
ment protocol, previously published evidence on the psycho-
metric and clinimetric properties of the tool, previous experi-
ence in mitochondrial disease (and in other similar diseases
with the respective measure), results from their own clinical
studies as well as pros and cons of using a particular outcome
measure in future studies.
After all the outcome measures had been presented, an
online survey was completed, designed to obtain the level
of consensus regarding inclusion and exclusion criteria,
definitions and the use of these specific outcome measures.
First, aspects of protocol design, including the time be-
tween measurements and the inclusion and exclusion
criteria, were voted for online. We predefined cut-offs in
advance, namely: a Bstrong consensus^ for a statement was
considered to have been reached when more than 90% of
scores were positive or negative (Byes^ or Bno^), Bgood
consensus^ was defined as more than 70% of the partici-
pants voting in the same direction. For the outcome mea-
sures, participants voted using a 5-point Likert scale to
indicate their level of agreement on each statement that this
test should be included as an instrument in the natural
history study (1 = absolutely disagree, 2 = disagree, 3 = no
judgment, 4 = more than agree, 5 = absolutely agree). The
pre-defined Bstrong consensus^ for a statement was con-
sidered to have been reached when both more than 70% of
scores were ≥ 4 and the mean score was > 4. In instances
where an expert did not have an opinion on one of the
items, (s)he was asked to leave the item open (so this item
would not be scored for this expert). If only one of these
two parameters were met, this was considered a Bgood
consensus^. If both parameters were not met in either the
positive or negative directions, then the statement was con-
sidered to lack consensus agreement (Mancuso et al.
2017). The questionnaire also contained a checkbox in
which participants were asked to select their top 5 priority
outcome measures for future studies. The results were
analysed anonymously. There were two voting rounds (af-
ter the presentations of the outcome measures and after
presenting and discussing the results of the first round)
for both mitochondrial myopathy and for mitochondrial
encephalo(myo)pathy.
Data availability Not applicable.
Workshop
The aim of the first day was to design a natural history
protocol for children with mitochondrial myopathy, with
a strong focus on which outcome measures to use. We
adopted the definition of primary mitochondrial myopathy
(PMM) from the PMM working group (Mancuso et al.
2017), namely that Bmitochondrial myopathies are geneti-
cally defined disorders leading to defects of oxidative
phosphorylation affecting predominantly, but not exclu-
sively, skeletal muscle^.
The first day started with a presentation about the clin-
ical spectrum of mitochondrial myopathy in children, illus-
t r a t i ng th e comp l ex pheno t ype s o f ch i l dhood
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mitochondrial myopathy. The most important complaints
include proximal myopathy, fatigue, exercise intolerance,
muscle pain, ophthalmoplegia, respiratory muscle weak-
ness and, rarely, rhabdomyolysis. Pure myopathy as the
sole clinical disease expression in children with mitochon-
drial disease is extremely rare.
Subsequently, the design and results of a recent study ex-
ploring outcome measures in children with mitochondrial my-
opathy (registration number NL59491.091.16) were present-
ed. Experience (including a literature review) with instruments
selected by the PMM working group which were not covered
by this study were also presented by (other) members of the
Delphi panel.
On the second day, outcome measures for a validation
study in children with mitochondrial encephalo(myo)pa-
thy were selected. First, the wide clinical spectrum of
mitochondrial encephalopathy, ranging from early fatal
epilepsy syndromes to the later onset mitochondrial en-
cephalopathy with lactic acidosis and stroke-like episodes
(also known as MELAS syndrome), was illustrated.
Subsequently, a literature review of and experience with
the proposed instruments in mitochondrial encephalo(my-
o)pathy were presented.
After a discussion on the domains to be covered, the feasi-
bility, reliability, validity and responsiveness of the tests pre-
sented and how to integrate these in a natural history protocol,
all participants voted onwhich tests should be included. These
results were subsequently discussed and items on which no
consensus was reached (either more than 70% of scores
were ≥ 4 or the mean score was > 4 but not both) were
discussed again.
Results of the Delphi-based process
Mitochondrial myopathy
The inclusion criteria for the natural history study include
all children with mitochondrial myopathy who are 0–
18 years and have a pathogenic mutation related to mito-
chondrial disease. Asymptomatic carriers may also be in-
cluded. An exclusion criterion is doubt about the pathoge-
nicity of the mutation. The time between measurements
was agreed as 6 months. It was agreed that, in rapidly
progressive and young patients (< 4 years), the time be-
tween measurements should be decreased to 3 months.
Motor function, endurance and muscle power were identi-
fied as the most important symptoms to be covered by
selected outcome measures. Only tests with more than
70% of the raters agreeing to include the test and/or an
average rating ≥ 4.0 were included in Tables 1 and 2.
Outcome measures were prioritised (Table 2) and the
sequence of the tests was determined for the natural history
protocol (available upon request).
Mitochondrial encephalo(myo)pathy
For the outcome measure validation study in children with
mitochondrial encephalo(myo)pathy, the time between the
training session for the child and the baseline measurement
was set as 2 weeks and the time between baseline and re-
test was set to be 1 week. At baseline, the child will be
measured by two independent raters to test intra-rater reli-
ability; all suitable measurements will be videotaped and
scored 6 weeks later to test inter-rater reliability. The re-
sults of the baseline and the outcome will be compared to
test the in-time variability over time (test–retest reliability).
Motor capacity, tone (spasticity, dystonia), ataxia, cogni-
tion, quality of life and caregiver burden were identified as
the most important domains to be assessed in children with
encephalopathy. Because of the wide range in age and
functional capacities, more than one outcome measure
were selected to be tested for each domain. For example,
the Alberta Infant Motor Scale (AIMS) was selected for
infants or young children with very low motor capacities,
while the other end of the spectrum is covered by the 6-min
walking test. Only the tests with either more than 70% of
the raters agreeing to include the test or an average rating ≥
4.0 are included (Tables 1 and 3).
Discussion
The aim of the natural history study is to monitor the motor
function, endurance, activities of daily life and muscle
power of children with mitochondrial myopathy. Special
attention will be paid to standardisation, to not only im-
prove the quality of the data obtained by this multi-centre
study, but also to avoid diurnal variation in e.g. ptosis,
muscle strength and attention span. Some critical points
in these standardisation procedures were discussed during
the workshop and will be implicated in the standard oper-
ating procedures of the natural history protocol. We have
selected a broad pallet of outcome measures, because it is
not clear yet on which clinical signs and symptoms future
clinical trials will focus. However, it was clear that there
should be a balance between the burden to patients and
parents and the broadness of information required. By se-
quencing the assessments based on the established priority
ranking, we would also allow centres with limited re-
sources to gather a minimum set of meaningful information
in a standardised manner. Since some tests, such as the 6-
min walk test, are subject to training effects (Casey et al.
2012), a training session is required in patients who have
not recently performed this test.
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The aim of the validation study in children with mito-
chondrial encephalo(myo)pathy is to obtain experience
with the selected instruments in affected patients. Based
on the results of this validation study, the inclusion and
exclusion criteria and the outcome measures for future nat-
ural history studies in this population will be discussed in a
future workshop. At this point, it was agreed that, because
of the lack of sufficient expertise in the present panel, no
Table 1 Results of the Delphi-based process
Consensus
Percentage
scores ≥ 4
Mean
score
Myopathy
6-min walk test 100% 4.4
30 s sit to stand test 100% 4.4
Children’s Hospital of Philadelphia
Infant Test of Neuromuscular
Disorders (CHOP-INTEND)
100% 4.7
Growth and weight gain 100% 4.6
Caregiver burden scale 100% 4.7
Grip strength 92% 4.2
New muscle endurance test
(developed by RCMM)
92% 4.0
International Paediatric Mitochondrial
Disease Scale (IPMDS)
91% 4.3
PedsQL (multidimensional fatigue) 91% 4.2
Newcastle Paediatric Mitochondrial
Disease Scale (NPMDS)
82% 4.0
Timed tests (stand up from floor) 77% 3.8
Hammersmith Functional Motor Scale 64% 3.6
Accelerometer 62% 3.5
Alberta Infant Motor Scale (AIMS) 60% 3.6
Gait measurement (GAITRite) 55% 3.4
PedsQL (general) 54% 3.5
Attain stand test (30 s) 46% 2.9
Timed tests (10-m walk) 46% 3.3
North Star Ambulatory Assessment 44% 3.2
Test of Masticating and Swallowing
Solids (TOMASS)
40% 3.2
Checklist individual strength (CIS) 38% 3.1
PedsQL (neuromuscular) 36% 3.2
Lateral step-up test (30 s) 31% 2.6
Childhood Myositis Assessment
Scale (CMAS)
31% 2.8
Gross Motor Function Measure
(GMFM)
27% 2.7
Pediatric Evaluation of Disability
Inventory (PEDI)
23% 2.6
Eyelid ptosis and ophthalmoparesis tests 18% 2.3
9-hole peg test 15% 1.8
Quantitative muscle power using
hand-held dynamometer
15% 2.3
Timed tests (5 stairs) 15% 2.2
Quantitative myasthenia gravis test 8% 2.0
6-min mastication test 0% 1.8
Encephalo(myo)pathy
Gross Motor Function Measure
(GMFM)
100% 4.7
Pediatric Evaluation of Disability
Inventory (PEDI)
100% 4.4
Spasticity: Tardieu scale 100% 4.2
Caregiver burden scale 100% 4.5
Barry–Albright Dystonia Scale 92% 4.1
Table 1 (continued)
Consensus
Percentage
scores ≥ 4
Mean
score
Scale for the assessment and rating
of ataxia (SARA)
85% 4.1
Growth and weight gain 85% 4.2
Alberta Infant Motor Scale (AIMS) 85% 3.9
Children’s Hospital of Philadelphia
Infant Test of Neuromuscular
Disorders (CHOP-INTEND)
85% 4.0
6-min walk test 85% 3.9
9-hole peg test 85% 3.8
Timed tests (10-m walk) 85% 3.8
Pediatric Outcomes Data Collection Instrument
(PODCI)
77% 3.7
30 s sit to stand test 77% 3.8
International Pediatric Mitochondrial
Disease Scale (IPMDS)
73% 4.1
CP classifications (CFCF, GMFCS,
MACS)
69% 3.8
Global assessment of three most
important symptoms
67% 3.8
Accelerometer 54% 3.5
Timed tests (stand up from floor) 46% 3.1
Perceive Recall Plan Perform (PRPP) 38% 2.8
Peabody vocabulary test 38% 3.2
PedsQL (general) 33% 3.1
Test of Masticating and Swallowing
Solids (TOMASS)
31% 3.0
Gait measurement (GAITRite) 31% 3.0
Timed tests (up and go) 31% 3.0
Hypertonia Assessment Scale 23% 2.8
Child Health Assessment Questionnaire
(CHAQ)
23% 2.8
KIDSCREEN 23% 2.7
Frontal assessment battery 23% 2.9
PedsQL (CP) 15% 2.7
Luria 15% 2.8
Spasticity: Ashworth scale 8% 2.6
Timed tests (5 stairs) 8% 2.5
Eyberg Child Behavior Inventory 8% 1.9
Gross Motor Function Measure (GMFM) 0% 2.2
The items on which no strong consensus was reached are shown in italics
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outcome measures for cognition were selected. It is recom-
mended that these measures are discussed in a separate
workshop to harmonise the instruments for this important
aspect of brain-related mitochondrial diseases.
The scientific rigour of expert consensus is fully dependent
on the evidence this consensus is based upon (Jorm 2015). In
this workshop, experts were able to base their opinion on a
thorough review of the experience with this outcome measure
inmitochondrial and non-mitochondrial diseases by one of the
other members of the Delphi panel, as well as the results of a
small validation study in four children with mitochondrial
myopathy. For paediatric mitochondrial encephalopathy, the
opinions were based on a thorough review of the experience
with this outcome measure in mainly non-mitochondrial dis-
eases. Therefore, the selected outcome measures will be
tested in a validation study in which more evidence for
mitochondrial diseases will be generated. Although our
workshop process deviated significantly from an optimum
Delphi process, including the standardisation of literature
review and formulation of questions, the diverse educa-
tional and medical background and geographic localisation
of the experts contributing to this workshop, as well as the
independent decisions of the experts during voting, were
compliant with the Delphi method (Jorm 2015).
Table 2 Proposed outcome measures for the natural history study in children with mitochondrial myopathy
Test ≥ 4 (%) Mean Priority adult-like Priority infantile
6-min walking test 100% 4.4 46%
30 s sit to stand test 100% 4.4 31%
Children’s Hospital of Philadelphia Infant Test of
Neuromuscular Disorders (CHOP-INTEND)
100% 4.7 92%
Growth and weight gain 100% 4.6 92% 92%
Caregiver burden scale 100% 4.7 92% 100%
Grip strength 92% 4.2 46%
New muscle endurance test (developed by RCMM) 92% 4 31%
International Paediatric Mitochondrial Disease Scale (IPMDS) 91% 4.3 54% 54%
PedsQL (multidimensional fatigue) 91% 4.2 46%
Newcastle Paediatric Mitochondrial Disease Scale (NPMDS) 82% 4 23% 31%
Timed tests (stand up from floor) 77% 3.8 11%
The item on which only good consensus was obtained is shown in italics
Table 3 Proposed outcome
measures for the explorative
study in children with
mitochondrial
encephalo(myo)pathy
Test ≥ 4 (%) Mean Priority
Gross Motor Function Measure (GMFM) 100% 4.7 100%
Pediatric Evaluation of Disabilities Inventory (PEDI-CAT) 100% 4.4 69%
Tardieu test for spasticity 100% 4.2 77%
Caregiver burden scale 100% 4.5 100%
Barry–Albright Dystonia Scale 92% 4.1 54%
6-min walk test 85% 3.9 54%
9-hole peg test 85% 3.8 23%
10-m walk or run test 85% 3.8 38%
Scale for the Assessment and Rating of Ataxia (SARA) 85% 4.1 54%
Growth and weight gain 85% 4.2 54%
Alberta Infant Motor Skills (AIMS; for young children) 85% 3.9 62%
Children’s Hospital of Philadelphia Infant Test of Neuromuscular
Disorders (CHOP-INTEND; for young children)
85% 4.0 62%
Newcastle Paediatric Mitochondrial Disease Scale (NPMDS) 85% 4.0 77%
30 s sit to stand test 77% 3.8 38%
Pediatric Outcomes Data Collection Instrument (PODCI) 77% 3.7 54%
International Pediatric Mitochondrial Disease Scale (IPMDS) 78% 4.0 62%
The items on which only good consensus was obtained are shown in italics
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Conclusion
In this two-day key opinion leader workshop on outcome
measures for children with mitochondrial diseases, we pro-
posed a set of outcome measures for a natural history study
in children with mitochondrial myopathy (Table 2), as well as
tests for children with mitochondrial encephalopathy
(Table 3). The latter tests will be included in a validation study
in Nijmegen, to study the feasibility, test–retest reliability and
inter- and intra-rater reliability in children with mitochondrial
encephalopathy.
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